TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription

University of Glasgow, Glasgow, Scotland, United Kingdom
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 10/2007; 104(38):14917-22. DOI: 10.1073/pnas.0702909104
Source: PubMed


Activation of RNA polymerase (pol) II transcription by c-Myc generally involves recruitment of histone acetyltransferases and acetylation of histones H3 and H4. Here, we describe the mechanism used by c-Myc to activate pol III transcription of tRNA and 5S rRNA genes. Within 2 h of its induction, c-Myc appears at these genes along with the histone acetyltransferase GCN5 and the cofactor TRRAP. At the same time, occupancy of the pol III-specific factor TFIIIB increases and histone H3 becomes hyperacetylated, but increased histone H4 acetylation is not detected at these genes. The rapid acetylation of histone H3 and promoter assembly of TFIIIB, c-Myc, GCN5, and TRRAP are followed by recruitment of pol III and transcriptional induction. The selective acetylation of histone H3 distinguishes pol III activation by c-Myc from mechanisms observed in other systems.

Download full-text


Available from: Natividad Gomez-Roman, Jul 02, 2014
  • Source
    • "Recently, strong evidence has implicated abnormal RNAP activity in cancer cells from breast and lung carcinomas [25] and in fibroblasts transformed by Simian virus 40 or other polyomavirus [26,27]. It is postulated that repression of tumour suppressors p53 and retinoblastoma [28] and/or activation of oncogene product c-Myc [29] may lead to enhanced RNAP activity in malignancy. However, the biological basis for an association between specific autoantibody subtypes against NRAP and malignancy in the context of SSc is unclear. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We assessed the profile and frequency of malignancy subtypes in a large single centre UK cohort for patients with scleroderma (systemic sclerosis; SSc). We evaluated the cancer risk among SSc patients with different antibody reactivities and explored the temporal association of cancer with the duration between onset of SSc and cancer diagnosis. A retrospective study of a well-characterised cohort of SSc cases attending a large tertiary referral centre was undertaken with clinical data collected through our clinical database and review of patient records. We evaluated development of all cancers in this cohort and comparison was assessed with the SSc cohort without cancer. The effect of demographics and clinical details including antibody reactivities were explored to find associations for development of cancer in SSc. Among 2177 patients with SSc, 7.1% of patients had a history of cancer. 26% were positive for anti-centromere antibodies (ACA), 18.2% were positive for anti-Scl70 antibodies and 26.6% were positive for anti-RNA polymerase III antibody (RNAP). The major malignancy subtypes were breast cancer (42.2%), haematological (12.3%), gastrointestinal (11.0%) and gynaecological cancers (11.0%). The frequency of cancers among patients with RNAP (14.2%) was significantly increased than those with anti-Scl70 (6.3%) and ACA (6.8%) (p < 0.0001 and p < 0.001 respectively). Among the patients, who were diagnosed with cancer within 36 months of the clinical onset of SSc, there were more patients with RNAP (55.3%) than other autoantibody specificities (ACA 23.5%; p < 0.008 and anti-Scl70 antibodies 13.6%, p < 0.002 respectively). Breast cancers were temporally associated with onset of SSc among patients with anti-RNAP and SSc patients with anti-RNAP had two-fold increased hazard ratio for cancers compared to patients with ACA (p < 0.0001). Our study confirmed independently, in the largest population examined to date, that there is an association with cancer among SSc patients with anti-RNAP antibodies in close temporal relationship to onset of SSc, which supports the paraneoplastic phenomenon in this subset of SSc cases. An index of suspicion should be cautiously maintained in these cases and investigations for underlying malignancy should be considered where clinically appropriate.
    Full-text · Article · Feb 2014 · Arthritis research & therapy
  • Source
    • "In support of this model, active tDNAs in vertebrates are located in nucleosome-depleted regions and flanking nucleosomes contain histone modifications associated with active promoters. In addition histone acetylases are recruited to mammalian tRNA genes suggesting that the mechanisms of insulator function in vertebrates may have similarities to those in S. cerevisiae [38] [39] [40] [41]. While numerous ETC sites have also been identified in mammalian cells [38] [40], it is currently unknown if these sites function as barrier insulators., Unlike tDNAs, ETC loci do not cluster along the DNA (JR unpublished results) and synthetic multimerized B-box sequences are not sufficient for barrier activity in murine cells [37] suggesting that these sites may have different roles but the role of these loci is unclear at this time. "
    [Show abstract] [Hide abstract]
    ABSTRACT: tRNA genes (tDNAs) have been known to have barrier insulator function in budding yeast, Saccharomyces cerevisiae, for over a decade. tDNAs also play a role in genome organization by clustering at sites in the nucleus and both of these functions are dependent on the transcription factor TFIIIC. More recently TFIIIC bound sites devoid of pol III, termed Extra-TFIIIC sites (ETC) have been identified in budding yeast and these sites also function as insulators and affect genome organization. Subsequent studies in Schizosaccharomyces pombe showed that TFIIIC bound sites were insulators and also functioned as Chromosome Organization Clamps (COC); tethering the sites to the nuclear periphery. Very recently studies have moved to mammalian systems where pol III genes and their associated factors have been investigated in both mouse and human cells. Short interspersed nuclear elements (SINEs) that bind TFIIIC, function as insulator elements and tDNAs can also function as both enhancer — blocking and barrier insulators in these organisms. It was also recently shown that tDNAs cluster with other tDNAs and with ETCs but not with pol II transcribed genes. Intriguingly, TFIIIC is often found near pol II transcription start sites and it remains unclear what the consequences of TFIIIC based genomic organization are and what influence pol III factors have on pol II transcribed genes and vice versa. In this review we provide a comprehensive overview of the known data on pol III factors in insulation and genome organization and identify the many open questions that require further investigation. This article is part of a Special Issue entitled: Transcription by Odd Pols.
    Full-text · Article · Sep 2012 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
  • Source
    • "Intriguingly, these MDSR genes are largely involved in nucleotide metabolism, ribosome biogenesis, RNA processing and DNA replication. In this regard, Myc also regulates RNA polymerases I and III mediated transcription in addition to its role in regulating RNA Pol II genes (Felton-Edkins et al., 2003; Gomez-Roman et al., 2003; Grandori et al., 2005; Kenneth et al., 2007). Thus, the protein biosynthetic machinery is inherent linked to Myc transcriptional activity and the balance between rRNA synthesis, ribosomal protein production, and the availability of adequate bioenergetics is essential for normal cell growth. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The MYC oncogene contributes to the genesis of many human cancers. Recent insights into its expression and function have led to therapeutic opportunities. MYC's activation by bromodomain proteins could be inhibited by drug-like molecules, resulting in tumor inhibition in vivo. Tumor growth can also be curbed by pharmacologically uncoupling bioenergetic pathways involving glucose or glutamine metabolism from Myc-induced cellular biomass accumulation. Other approaches to halt Myc on the path to cancer involve targeting Myc-Max dimerization or Myc-induced microRNA expression. Here the richness of our understanding of MYC is reviewed, highlighting new biological insights and opportunities for cancer therapies.
    Full-text · Article · Mar 2012 · Cell
Show more